Roivant posted minimal revenue and a net loss in Q3 fiscal 2026 as the company continued to invest heavily in R&D to advance its clinical pipeline, while maintaining a strong liquidity position.

Roivant Sciences faced a challenging quarter with increased R&D expenses and a narrowed net loss. Revenue declined compared to the previous year, but strong pipeline momentum, particularly for brepocitinib and Immunovant’s programs, provided optimism.

Roivant posted modest revenue alongside a larger operating loss as it advanced multiple late-stage programs. GAAP EPS was -$0.33 and non-GAAP adjusted EPS was approximately -$0.25 based on adjusted net loss and shares outstanding. The company ended the quarter with a robust cash and investments balance and continued share repurchases.

Roivant Sciences ended Q4 2025 with a net loss of $206.5 million as operating expenses surged due to higher R&D and G&A costs. Revenue dipped slightly from the prior year. Adjusted EPS came in below zero, reflecting ongoing investment in its late-stage pipeline.

Roivant Sciences saw a revenue decline of 42% year-over-year, driven by lower collaboration revenue. The company reported a net income of $118.1 million, significantly lower than the previous year's $5.07 billion due to a one-time gain from the Telavant sale in the prior year. Operating expenses rose due to higher R&D investments, particularly in its anti-FcRn franchise. Despite the losses, Roivant maintains a strong liquidity position with $5.2 billion in cash and marketable securities.

Roivant reported a net revenue of $4.475 million. The company's R&D expenses were $143.1 million, and G&A expenses were $202.9 million. Roivant reported consolidated cash, cash equivalents and marketable securities of approximately $5.4 billion at September 30, 2024. Roivant continued to return capital through share repurchases with $106M purchased for the quarter.

Roivant Sciences reported a net income of $57.5 million for the quarter ended June 30, 2024, compared to a net loss of $327.8 million for the same period in 2023. VTAMA net product revenue was $18.4 million. The company's consolidated cash, cash equivalents, and restricted cash stood at $5.7 billion as of June 30, 2024.

Roivant reported a productive fourth quarter, with positive data for brepocitinib in NIU and progress in Immunovant's IMVT-1402 development. VTAMA net product revenue was $19.3M for the quarter and $75.1M for the fiscal year. The company has $6.6B in cash, supporting cash runway into profitability.

Roivant reported a net income of $5.1 billion for the quarter ended December 31, 2023, driven by the sale of Telavant to Roche for $7.1 billion. VTAMA net product revenue was $20.7 million. The company's consolidated cash, cash equivalents, and restricted cash stood at $6.7 billion as of December 31, 2023.

Roivant Sciences reported its Q2 2024 financial results, highlighted by the sale of Telavant to Roche for $7.1 billion upfront and a $150 million milestone payment. VTAMA net product revenue reached $18.4 million, and the company's cash position was approximately $1.4 billion at the end of September. The company is anticipating key data readouts from clinical programs.

Roivant reported positive data from the chronic period of the Phase 2b study of RVT-3101 in ulcerative colitis and from the ADORING 1 trial evaluating VTAMA in patients with atopic dermatitis. The company initiated the TAHOE Phase 2 study of RVT-3101 in Crohn’s disease and the Phase 1 study of IMVT-1402 in healthy volunteers. VTAMA net product revenue was $16.7M for the quarter. Roivant's consolidated cash, cash equivalents and restricted cash was $1.4B at June 30, 2023.

Roivant Sciences reported VTAMA net product revenue of $13.7 million for the quarter ended March 31, 2023, with a 25% gross-to-net yield. The company's cash, cash equivalents, and restricted cash stood at $1.7 billion as of March 31, 2023.

Roivant Sciences reported $9.2M in net product revenue from VTAMA, expanded VTAMA payor coverage to 57% of commercial lives, and established a partnership with Pfizer to develop RVT-3101. A $230M equity financing was completed to advance TL1A programs.

Roivant Sciences reported a net loss of $315.9 million for the quarter ended September 30, 2022. VTAMA net product revenue was $5.0 million. The company's cash runway is expected to extend into the second half of calendar year 2025.

Roivant Sciences reported its financial results for the first quarter ended June 30, 2022. VTAMA launch showed strong early signals with approximately 14,000 prescriptions in the first eleven weeks. Positive topline results were reported from Torii Pharmaceutical and Japan Tobacco's study of tapinarof in atopic dermatitis.

Roivant Sciences reported a net loss of $291.3 million for the quarter ended March 31, 2022. The company had $2.1 billion in cash and cash equivalents as of March 31, 2022. VTAMA was approved by the FDA for the treatment of plaque psoriasis.

Roivant Sciences reported its financial results for the third fiscal quarter ended December 31, 2021. The company had cash and cash equivalents of approximately $2.2 billion as of December 31, 2021. R&D expenses were $153.5 million, and G&A expenses were $115.5 million. Net loss for the quarter was $306.1 million.

Roivant Sciences reported its financial results for the second fiscal quarter ended September 30, 2021. The company's cash and cash equivalents increased to $2.5 billion. Roivant closed its business combination with Montes Archimedes Acquisition Corp. and began trading on Nasdaq under the ticker "ROIV."

Roivant Sciences reported its financial results for the fiscal quarter ended June 30, 2021. The company highlighted the upcoming closing of the business combination with MAAC, the FDA's acceptance of Dermavant's NDA, the dosing of the first patient in a Phase 3 trial, the completion of Datavant's merger with Ciox Health, and a strategic investment in Immunovant.